Drug firm Lupin has received approval from the US health regulator to market Pitavastatin tablets used for lowering cholesterol.
In a BSE filing, Lupin said it has received 505 (b) (2) NDA approval for its Nikita Pitavastatin tablets 1mg, 2mg and 4mg from the United States Food and Drug Administration (USFDA).
The company said Nikita tablets are Pitavastatin sodium, an alternate salt product of Kowa Company Ltd’s Livalo tablets.
“It is a new option for patients with primary hyperlipidemia or mixed dyslipidemia as an adjunction therapy to diet to reduce elevated total cholesterol, low-density lipoprotein cholesterol, apolipoprotien B, triglycerides and to increase high-density lipoprotein cholesterol,” it said.
According to IMS MAT June 2017 data, Livalo tablets had US sales of $272 million, it added.
Shares of Lupin Ltd were trading at Rs 961.95 per scrip in morning trade on BSE, down 1.28 per cent down from its previous close.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.